|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600127034 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-23 11:38:18 |
|
注册时间: Date of Registration: |
2026-06-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于IVUS/OCT一体机的支架内再狭窄机制评估及其对围术期再干预策略优化的影响 |
|
Public title: |
Mechanism-Based Assessment of In-Stent Restenosis Using a Hybrid IVUS/OCT System and Its Impact on Optimizing Periprocedural Reintervention Strategies |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于IVUS/OCT一体机的支架内再狭窄机制评估及其对围术期再干预策略优化的影响 |
|
Scientific title: |
Mechanism-Based Assessment of In-Stent Restenosis Using a Hybrid IVUS/OCT System and Its Impact on Optimizing Periprocedural Reintervention Strategies |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨雪瑶 |
研究负责人: |
张闽 |
|
Applicant: |
Yang Xueyao |
Study leader: |
Zhang Min |
|
申请注册联系人电话: Applicant telephone: |
+86 188 0016 7150 |
研究负责人电话:
Study leader's |
+86 135 2028 2850 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yxy1231994@163.com |
研究负责人电子邮件: Study leader's E-mail: |
minjun1977@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市通州区宋庄南一街225号 |
研究负责人通讯地址: |
北京市通州区宋庄南一街225号 |
|
Applicant address: |
No. 225, South First Street, Songzhuang, Tongzhou District, Beijing |
Study leader's address: |
No. 225, South First Street, Songzhuang, Tongzhou District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属北京安贞医院 |
||
|
Applicant's institution: |
Beijing Anzhen Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京安贞医院 |
||
|
Affiliation of the Leader: |
Beijing Anzhen Hospital, Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KS2026040 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京安贞医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Beijing Anzhen Hospital, Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-05-13 00:00:00 | ||
|
伦理委员会联系人: |
吴朝阳 |
||
|
Contact Name of the ethic committee: |
Wu Chaoyang |
||
|
伦理委员会联系地址: |
北京市通州区宋庄南一街225号 |
||
|
Contact Address of the ethic committee: |
No. 225, South First Street, Songzhuang, Tongzhou District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6445 6214 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
首都医科大学附属北京安贞医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Anzhen Hospital, Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市通州区宋庄南一街225号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 225, South First Street, Songzhuang, Tongzhou District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
全景恒升(北京)科学技术有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Panovision (Beijing) Science and Technology Co., LTD |
||||||||||||||||||||||
|
研究疾病: |
冠心病 |
||||||||||||||||||||||
|
Target disease: |
Coronary Artery Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
基于IVUS-OCT一体机多模态腔内影像,构建并验证用于金属支架ISR机制评估的多参数组合模型,形成可推广的标准化表型—机制评估体系,为围术期再干预策略优化及术后危险因素管理提供影像学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the multimodal intracardiac imaging of the IVUS-OCT integrated device, a multi-parameter combination model for evaluating the mechanism of metal stent ISR was constructed and validated. A standardized phenotypic-mechanism evaluation system was formed, providing imaging-based evidence for optimizing perioperative re-intervention strategies and managing postoperative risk factors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄 ≥18岁; 2.既往植入金属支架(BMS或DES)且拟行冠脉造影; 3.冠脉造影提示支架内再狭窄(ISR):支架段及近远端 5 mm 边缘狭窄 >50%; 4.术中可完成IVUS/OCT一体机成像(支架段及近远端边缘段); 5.能够理解研究内容并签署知情同意书,且同意完成12个月随访及实验室复查。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 18 years; 2. Previous implantation of metallic stents (BMS or DES) and planned for coronary angiography; 3. Coronary angiography indicates in-stent restenosis (ISR): > 50% stenosis at the stent segment and the 5 mm margins proximal and distal; 4. Intraoperative IVUS/OCT integrated imaging can be completed (at the stent segment and the marginal segments proximal and distal); 5. Able to understand the research content and sign the informed consent form, and agree to complete 12-month follow-up and laboratory re-examination. |
||||||||||||||||||||||
|
排除标准: |
1.合并需紧急救治且不允许额外成像时间的危重情况(如难以维持血流动力学稳定等); 2.对影像检查相关材料(如造影剂/冲洗液等)明确禁忌且无法替代; 3.目标病变导丝/导管无法通过或预判无法安全完成一体机成像; 4.研究者认为不适合入组的其他情况(如依从性差、无法完成随访等)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. For critical cases that require urgent treatment and do not allow additional imaging time (such as difficulties in maintaining hemodynamic stability, etc.); 2. For materials related to imaging examinations (such as contrast agents / flushing solutions) that are clearly contraindicated and cannot be replaced; 3. If the target lesion guide wire / catheter cannot pass or it is predicted that integrated machine imaging cannot be safely completed; 4. Other situations that the researcher deems unsuitable for inclusion (such as poor compliance, inability to complete follow-up, etc.). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-07-01 00:00:00至 To 2029-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-07-01 00:00:00 至 To 2029-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据录入采用电子病例报告表(eCRF),所有受试者按唯一编码编号,去除可识别个人身份信息。该研究所产生的数据采用电子数据采集系统(Electronic Data Capture,EDC)进行录入及保存,EDC只对名单中列出的人员授权,使用个人帐号和密码登录基于互联网的数据管理系统。管理和操作EDC重要信息的工作人员需要与研究组签订保密协议。EDC管理工作人员不得擅自修改或删除现有信息。未授权人员不能访问EDC系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data entry is conducted using electronic case report forms (eCRF). All subjects are assigned a unique code number and all identifiable personal information is removed. The data generated by this research is entered and stored using the Electronic Data Capture (EDC) system. EDC is only authorized to access the personnel listed in the list, and they log in to the internet-based data management system using personal accounts and passwords. Staff responsible for managing and operating the important information of EDC need to sign a confidentiality agreement with the research team. EDC management staff are not allowed to modify or delete existing information. Unauthorized personnel cannot access the EDC system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |